• Onpoint Ecommerce

  Led · Series A · Apr 2020

  OnPoint Consulting, Ltd., Co. is a Vietnam-based e-commerce enabler that provides a one-stop solution to help consumer brands accelerate online growth across e-commerce marketplaces, social media platforms, and brand-owned websites. Founded in 2017, the company offers omni-channel e-commerce solutions and aims to create sustainable, customer-centric value through continuous innovation. In June 2022 OnPoint raised $50.0M in a Series B led by SeaTown Private Capital Master Fund. SeaTown Private Capital Master Fund is managed by SeaTown Holdings International, an indirect wholly-owned subsidiary of Temasek Holdings. OnPoint said it will use the proceeds to expand its e-commerce enabling ecosystem, strengthen talent and capabilities, and develop emerging technologies with a data-driven approach. The company lists its website as https://www.onpoint.vn/. OnPoint is a Vietnam-based e-commerce enabler. According to an announcement, the company has raised over $8 million in a Series A funding round. The Series A was led by Kiwoom Investment and Daiwa-SSIAM Vietnam Growth Fund II L.P. The funding information was reported in the announcement. The article does not provide additional operational metrics or detailed use-of-proceeds. The company is described solely in the context of this fundraising announcement.

• ASLAN Pharmaceuticals

  Participated · Equity · Jul 2016

  ASLAN Pharmaceuticals is a biopharmaceutical company developing ASLAN003 for autoimmune gastrointestinal and skin diseases and certain skin conditions. The company has closed a secured loan facility with K2 HealthVentures providing up to $45 million of secured debt financing. The facility includes a $20 million initial term loan funded at closing and a further $25 million subject to certain terms and conditions. ASLAN intends to use the proceeds to advance the clinical development of ASLAN003 and for general corporate purposes. The company expects to initiate a Phase 2 clinical trial of ASLAN003 in inflammatory bowel disease in early 2022. The loan provides near-term funding to support those planned clinical activities. ASLAN Pharmaceuticals is a biotech focused on developing immunotherapies and targeted agents for tumour types highly prevalent in Asia. Its pipeline comprises four novel therapeutic agents, with lead drug varlitinib currently in phase 2 trials for cholangiocarcinoma, gastric cancer and breast cancer. Proceeds from the new financing will be used to support clinical development of the pipeline. The company said the financing bolsters its financial position and will accelerate progress across its clinical programme. ASLAN has raised over US$100 million to date, including a US$43 million Series C in December 2015 led by Accuron (a Temasek subsidiary). The announcement was released from Singapore and the company is pursuing growth in Taiwan and the region. Aslan Pharmaceuticals is a Singapore-based biotech focused on developing immunotherapies and targeted agents for tumor types prevalent in Asia. The company maintains a proprietary pipeline of four development-stage candidates addressing multiple indications including gastric and breast cancers and inflammatory diseases. Its most advanced programs are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer and trials in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint target, and cMET. Aslan also operates a global medical device and diagnostics division, Accuron MedTech, led by Abel Ang. The company is led by CEO Dr. Carl Firth and plans to use recent proceeds to accelerate clinical development of ASLAN001, which received Orphan Drug Designation in cholangiocarcinoma from the US FDA.

No current team members are available.